Fountain Therapeutics builds a pipeline of disease-modifying therapeutics for chronic degenerative diseases using a cell-based, AI-driven technology platform that leverages machine learning and computer vision alongside biology of aging. The platform enables precise mapping of cellular biologic age and extraction of cellular features to identify novel targets and disease biomarkers. Fountain has translated these insights into an unbiased drug discovery and development engine aimed at therapies that restore cellular resilience. The company announced a $15 million Series A-2 financing, bringing its total Series A funding to $26 million. Proceeds will support expansion of the leadership team, continued R&D activities, pre-clinical research, and further development of its platform and pipeline. The announcement was released from San Francisco. Fountain Therapeutics builds a pipeline of therapeutics intended to treat age-related diseases by reversing cellular age. The company uses a cell-based, AI-driven technology platform that extracts cellular features to provide insights into the aging process. Its leadership includes CEO John Dimos, Ph.D. Fountain plans to use recent funding to expand its senior leadership team and enhance its technology platform capabilities. The company intends to advance novel therapeutics identified by the platform through preclinical testing in animal models. As of the announced financing, Fountain has increased its Series A funding to a total of $11M.

Total raised

$21M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2021